This review compared percutaneous coronary interventions to each other or medical therapy for the treatment of nonacute coronary artery disease. The authors concluded that there was support for the use of medical therapy as an initial management strategy. Review limitations make the reliability of the pooled results uncertain, but the overall conclusion was suitably cautious and appears appropriate.
Study selection
Randomised controlled trials (RCTs) of PTCA, bare metal stents or drug eluting stents compared to each other or medical therapy in patients who had symptomatic or asymptomatic non-acute coronary artery disease were eligible for inclusion. Included trials had to have at least 10 patients in each group, comparing at least two of the treatments of interest. Trials were excluded if they: recruited patients within 72 hours of a myocardial infarction (MI); were restricted to patients with diabetes; focused on venous bypass grafts, in-stent restenosis, or left main disease; compared two techniques of the same type (for example, two bare metal stents); used different types of percutaneous coronary intervention in the same group unless at least 85 per cent of the comparator group were given one type. Outcomes of interest were mortality, MI, revascularisation and coronary artery bypass graft (CABG). Where reported, the mean age of participants ranged from 52 to 69 years, 59 to 100 per cent were male, 0 to 56 per cent had diabetes and 10 to 100 per cent had multi-vessel disease. Most trials compared bare metal stents with PTCA or drug eluting stents with bare metal stents. Trials comparing PTCA with medical therapy tended to have younger patients and fewer patients with unstable angina than other comparisons.
The authors did not state how studies were selected for the review, or how many reviewers performed the study selection.
Assessment of study quality
The authors did not state that they systematically assessed validity; blinding was the only quality criteria stated as being assessed.
Data extraction
The number of patients experiencing each outcome was extracted, and a relative risk (RR) and 95% confidence intervals (CI) were calculated for each study.
Data were extracted by one reviewer and checked by a second; discrepancies were resolved by consensus.
Methods of synthesis
Pooled RR and 95% CI were calculated from the RCTs with direct comparisons using a random-effects model. A mixed treatment analysis was conducted which combined direct and indirect evidence, using a two-level linear mixed effects model with heteroscedastic errors. Heterogeneity was assessed using the I 2 statistic. Subgroup and sensitivity analyses were conducted investigating: type of drug eluting stents; the proportion of patients with unstable angina;
